Hiv Clinical Trial
Official title:
"Sống Vui, Live Happily": A Psychosocial Tele-health Intervention to Address Multi-level Stigma Among Youth Living With HIV in Vietnam
Verified date | May 2022 |
Source | University of New England |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall goals of the study are to deepen understanding of the spectrum of stigma experienced by YLHIV in Vietnam, to develop a multi-level stigma intervention for YLHIV delivered by telephone, and to evaluate the feasibility, acceptability, and preliminary efficacy of the intervention on intra- and inter-personal stigma, psychological wellbeing, and treatment adherence. The project has the following Specific Aims: 1. Adapt a psychosocial stigma-reduction intervention for YLHIV in Vietnam based on cognitive-behavioral therapy principles and delivered by telephone, using input from youth during intervention development. 2. Assess the feasibility, acceptability and preliminary efficacy of this innovative approach to reduce stigma, and improve psychosocial wellbeing and ART adherence among YLHIV through a small pre-post study. 3. Explore the multiple facets of stigma experienced by YLHIV in Vietnam and their relationships with ART adherence and psychosocial wellbeing via quantitative surveys and electronic adherence monitoring. The study will assess the feasibility and acceptability of this approach among YLVIV in Vietnam, and generate preliminary evidence for the potential effect of the intervention on important endpoints including stigma, psychosocial wellbeing, adherence, CD4 count, and viral load (VL).
Status | Completed |
Enrollment | 38 |
Est. completion date | May 15, 2022 |
Est. primary completion date | May 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 24 Years |
Eligibility | Inclusion Criteria: - are between 18 and 24 years old - are a patient at the OPC - are expected to remain in care at the OPC for 3 months minimum(?) - are currently on ART - have primary responsibility for taking their own medications, - self-report intrapersonal stigma via a brief screening questionnaire, - are able to complete a short phone call from the location where they intend to be when participating in coaching sessions, - agree to follow all study procedures, AND - provide informed consent. Exclusion Criteria: - are below the age of 18 years or above the age of 24, - are not currently on ART, - live outside the clinic catchment area, - are identified as having severe mental health issues as identified through screening, OR - are not willing to provide informed consent. |
Country | Name | City | State |
---|---|---|---|
Vietnam | Institute for Social Development Studies | Hanoi |
Lead Sponsor | Collaborator |
---|---|
University of New England | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Fogarty International Center of the National Institute of Health, Institute for Social Development Studies (ISDS) |
Vietnam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intrapersonal (self) Stigma | modified 21-item self stigma subscale of Vietnam Stigma Index Studies instrument (People living with HIV: Stigma Index 2014; higher score=worse outcome) | change between Week 1-Week 12 | |
Primary | Interpersonal Stigma | modified 21-item enacted stigma subscale of Vietnam Stigma Index Studies instrument (People living with HIV: Stigma Index 2014; higher score=worse outcome) | change between Week 1 and Week 12 | |
Primary | Depression | 7-item depression subscale of the Depression, Anxiety and Stress Scale (DASS-21; higher score=worse outcome) | change between Week 1 and Week 12 | |
Primary | Anxiety | 7-item depression subscale of the Depression, Anxiety and Stress Scale (DASS-21; higher score=worse outcome) | change between Week 1 and Week 12 | |
Primary | Adherence | %=95% on-time adherence | Week 12 (endline) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |